Effectiveness of serogroup C meningococcal conjugate vaccine: A 7-year follow-up in Quebec, Canada

Pediatric Infectious Disease Journal

Volumn 30, Issue 7, 2011, Pages 566-569

  De Wals, Philippe ^a,b,c   Deceuninck, Geneviève ^b   Lefebvre, Brigitte ^c   Boulianne, Nicole ^b,c   De Serres, Gaston ^a,b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

conjugate vaccine; effectiveness; evaluation; meningococcus

Indexed keywords

C MENINGOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BIRTH; CANADA; CHILD; DRUG EFFICACY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MENINGOCOCCAL C DISEASE; MENINGOCOCCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THERAPY DELAY;

EID: 79959721588     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31820e8638     Document Type: Article

References (18)

1. De Wals P, Dionne M, Douville-Fradet M, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the province of Quebec, Canada. Bull WHO. 1996;74:407-411.
2. De Wals P, Deceuninck G, De Serres G, et al. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. Clin Infect Dis. 2005;40:1116-1122. (Pubitemid 40490235)
3. Tsang RS, Law DK, Henderson AM, et al. Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis. J Infect Dis. 2006;194:1791-1792. (Pubitemid 44902013)
4. De Wals P, Deceuninck G, Boulianne N, et al. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA. 2004;292:2491-2494. (Pubitemid 39552674)
5. Boulianne N, Audet D, Ouakki M. Enquête sur la couverture vaccinale des enfants québécois en 2006. Institut national de santé publique du Québec, Québec 2007. Available at: http://www.inspq.qc.ca/pdf/publications/678-VaccinationEnfantsen2006.pdf.
6. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev. 1988;10:212-241. (Pubitemid 18262846)
7. Rivest P, Sagot B, Bedard L. Evaluation of the completeness of reporting of invasive meningococcal disease. Can J Public Health. 1999;90:250-252. (Pubitemid 29403232)
8. Trotter C, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8:851-861.
9. Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(suppl 2): B20-B29.
10. Moulton LH, O'Brien KL, Reid R, et al. Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study. J Biopharm Stat. 2006;16:453-462. (Pubitemid 43995555)
11. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines. 2006;5:269-275. (Pubitemid 44179956)
12. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
13. Campbell H, Andrews N, Borrow R, et al. Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modelling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840-847.
14. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9:213-220.
15. NACI (National Advisory Committee on Immunization). Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. Can Commun Dis Rep. 2009;36(ACS-3):1-39.
16. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008;336:1487-1491. (Pubitemid 351977021)
17. Thomas HL, Andrews N, Trotter C, et al. Meningococcal C booster not recommended by evidence. BMJ. 2008;337:a1139.
18. CDC. Recommended immunization schedules for persons aged 0 through 18 years-United States, 2009. Morb Mortal Wkly Rep. 2009;57:1409-1412.